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Cloning of 2 novel Dido transcripts. (A) Dido transcript expression was analyzed in murine (left) and human (right) cell lines by hybridization with 
a probe corresponding to full-length Dido1. Blots were stained with methylene blue to normalize the amounts loaded. (B) Schematic representa-
tion of Dido1, Dido2, and Dido3. Different colors indicate common and specific nucleotide sequences. (C and D) Flag-tagged Dido1, Dido2, and 
Dido3 expression was analyzed in immunoblot (C) or immunofluorescence (D) of transfected 293T cells using anti-Flag M2 mAb. Molecular size 
markers are indicated at left (C). Magnification, ×100.
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Alignment of murine Dido1, Dido2, and Dido3 predicted amino acid sequences. Boxes indicate the bipartite NLS sequence (black), Zn-finger 
domains (blue), and TFS2M domains (green). The asterisk at M423 indicates the first available ATG codon in truncated Dido3.
research article





























both  gene  copies  had  been 
disrupted were identified by 




that  Didoneo/neo  cells  lacked 
mDido1  and mDido2  mRNA 
(Figure  3C)  but  retained  a 





detected  in  Didoneo/neo  than 
in Dido+/+ cells	 (not  shown). 
cDNA  sequencing  showed 
that  this  transcript  lacked 






































Targeted disruption of the mDido locus. (A) Scheme showing exon-intron structure of the Dido locus. Colors 
indicate common and specific nucleotide sequences. Noncanonical splicing events are indicated with stars. 
To target the murine Dido locus, a region containing exon IV and most of exon III was deleted and replaced 
by a neoresistance cassette. A restriction map is shown of WT mouse Dido. Arrow indicates the position 
of M423. ERV, EcoRV; ERI, EcoRI. (B) Southern blot hybridization. Mouse Dido disruption by homologous 
recombination resulted in a 5.5-kb band using EcoRV-digested genomic DNA. (C) mDido transcript expres-
sion was analyzed in WT (+/+), Dido+/neo (+/neo), and Didoneo/neo (neo/neo) mouse tissues by hybridization 
with a probe common to the 3 mDido transcripts. The blot was stained with methylene blue to control RNA 
loading. (D) mDido3 transcript expression was analyzed on the same blot with an mDido3-specific probe.
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A variety of lesions are found in spleens 
of affected Dido-targeted mice. (A) 
Spleen sections from WT and diseased 
Didoneo/neo mice were immunostained 
with anti-B220 mAb and hematoxy-
lin-counterstained. h, healthy; d, dis-
eased. (B) Spleen sections from WT 
and diseased Didoneo/neo mice were H&E 
stained. Note the abundance of myeloid 
cells with atypical nuclei (arrows). Mag-
nification, ×6 (A); ×20 (B). (C) Spleen 
weight of WT, healthy, and diseased 
Dido+/neo and Didoneo/neo mice. (D) Flow 
cytometry analysis of splenocytes from 
WT (C38) and diseased Didoneo/neo (C28, 
C40, and C61) mice stained with mAbs 
against CD11b, Gr-1, Ter119, and con-
trol antigens. Forward scatter (FSC) ver-
sus side scatter (SSC), CD11b versus 
Gr-1, and Ter119 versus control dot plots 
are shown. Numbers in boxes indicate 
percentages of cells within each gate.
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Representative sample of lesion heterogeneity in diseased Dido-targeted mice
	 WT	 +/neo	 neo/neo
	 mean	±	SD	 B94	 C1	 C14	 B90	 C4	 C12	 C16	 C19	 C28	 C40	 C60	 C61	 C62
Bone	marrow
Low colony formationA 2.4 ± 0.75 1.0 0.6 1.7 2.4 0.4 2.3 0.8 ND 1.3 0.2 1.5 1.9 0.6
 2.1 ± 1.25 1.8 0.7 1.7 1.2 1.0 1.5 0.8 ND 1.1 0.3 0.7 2.1 1.3
MonocytosisB 1.9 ± 0.8 1.8 10.1 0.4 2.9 1.9 3.7 3.2 2.1 7.3 24.0 1.9 3.1 5.6
GranulocytosisC 43.7 ± 16.1 65.5 16.6 90.9 33.1 64.9 45.4 41.7 73.9 71.7 48.0 63.1 64.8 40.5
Ab. erythropoiesisD 34.9 ± 11 26.5 49.2 6.7 42.3 17.7 28.7 49.7 17.2 25.9 22.0 23.8 10.2 22.6
Spleen
SplenomegalyE 0.18 ± 0.07 0.25 1.13	 1.08	 0.46 0.22 0.40	 0.32	 0.41 0.90 0.19 0.29	 0.35 0.34
MonocytosisB 5.5 ± 1.9 3.6 10.5 1.1 9.0 5.1 4.4 12.8 2.5 11.5 18.0 7.8 9.6 7.8
GranulocytosisC 12.3 ± 8.1 34.2 15.2 57.1 14.4 20.1 20.4	 22.1	 47.6 32.6 13.0 26.9	 31.5 17.1
ErythrocytosisF 13.5 ± 6.7 5.4 13.3 25.4 6.5 19.7 17.1 15.9 23.7 32.4 8.0 13.6 11.1 7.6
Blood
AnemiaG 11.6 ± 0.8 10.5 7.2	 9.4 11.3 13.0 10.9 11.1 11.4 9.7	 8.4 11.0 10.1 11.8
 160 ± 14 134 128	 116 146 167 154 163 140 109	 126 152 144 164
MonocytosisH 0.5 ± 0.2 1.4 0.7 4.2 0.6 0.8 0.1 0.7 0.7 2.1 0.5 0.3 0.9 0.2
GranulocytosisH 2.1 ± 1.4 5.2 17.7 30.3 1.6 2.9 1.3 1.8 12.2 21.9 1.6 2.2 3.3 2.9
Mouse codes and genotypes are shown at top; values in red indicate lesions in each mouse. Values for WT mice (n = 15) are mean ± SD. Ab, abnormal; ND, 
not determined. ACFU-GM (top line) and/or BFU-E (bottom line) colony/cluster ratios were 50% lower than in WT mice. BPercentage of monocytes in indi-
cated organs was at least 50% higher than in WT mice. CPercentage of granulocytes in indicated organs was at least 50% higher than in WT mice. DTer119-
positive cells were at least 30% lower than in WT mice, or Ter119-bright cells were absent (C40). ESpleen weight was at least 50% higher than in WT mice. 
FPercentage of Ter119-positive cells in spleen was at least 50% higher than in WT mice. GErythrocyte number was less than 10 × 1012/l (top line), and hemo-
globin levels were less than 130 g/l (bottom line). HMonocyte number was greater than 1 × 109/l and granulocyte number was greater than 7 × 109/l.
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Bone marrow of affected Dido+/neo and Didoneo/neo 
mice displays heterogeneous lesions. (A) Flow 
cytometry analysis of cells isolated from bone mar-
row of WT (C38) and 2 representative diseased 
Didoneo/neo mice (C28 and C40) stained with mAbs 
against CD11b, Gr-1, Ter119, and control anti-
gens. FSC versus SSC, CD11b versus Gr-1, and 
Ter119 versus control dot plots are shown. Num-
bers in boxes indicate percentages of cells within 
each gate. (B) Bone marrow sections from WT and 
diseased Didoneo/neo mice were H&E stained. Note 
cells with atypical nuclei (arrows). Magnification, 
×20. (C) The colony/cluster ratio is shown for gran-
ulocyte-macrophage and erythrocyte bone marrow 
progenitors from WT mice as well as from healthy 
and diseased Dido+/neo and Didoneo/neo mice. 
*P < 0.006; +P < 0.02.
Figure 6
Targeting mDido causes MDS/MPDs in mice. Mice showing 3 or more 
spleen or bone marrow symptoms were diagnosed with MDS/MPDs. 
Percentages of surviving, disease-free mice are shown as Kaplan-Meier 
curves for WT (n = 30), Dido+/neo (n = 86), and Didoneo/neo (n = 38) mice.
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Targeting of murine Dido causes a transplantable disease
	 Donor	mice
	 +/+	 neo/neo
Recipient	mice	 A1	 A2	 B1	 E1	 E2	 C1	 C2	 D1	 D2	 F1	 F2
Bone	marrow
Low colony formationA 3.1 2.7 4.1 4.2 2.9 1.2 1.5 1.0	 0.9 1.7 1.8
 2.6 1.8 2.2 2.3 1.6 1.1 1.5 1.1	 0.9 1.2 1.4
MonocytosisB 1.7 1.7 1.3 1.1 1.3 0.9 1.4 1.4 1.5 2.8 2.5
GranulocytosisC 32.8 30.7 50.1 39.6 56.5 36.3 32.7 61.9 56.0 65.9	 78.1
Ab. erythropoiesisD 44.5 42.4 25.8 35.8 29.0 51.5 53.2 24.7 24.5 19.3 9.3
Spleen
SplenomegalyE 0.13 0.10 0.08 0.05 0.09 0.27 0.21 0.12 0.08 0.10 0.06
MonocytosisB 4.9 4.4 2.2 7.9 4.2 0.8 2.2 3.9 3.5 4.0 4.8
GranulocytosisC 8.3 6.9 14.5 15.6 36.6 10.1 5.3 47.2	 47.7	 42.5	 85.6
ErythrocytosisF 40.3 9.7 37.4 18.3 24.8 84.2	 79.6 22.7 33.3 38.9 2.8
Blood
AnemiaG 9.3 11.9 13.4 11.3 11.8 4.7	 5.6 ND 12.4 11.3 9.9
 126 148 157 146 143 67	 89 ND 156 133 112
MonocytosisH 0.1 0.8 0.1 1.4 0.2 0.4 0.2 ND 1.5 0.5 1.1
GranulocytosisH 3.1 1.2 3.4 3.8 2.1 2.8 3.0 ND 12.0 2.6 8.3
Bone marrow cells from healthy WT (+/+) or diseased Didoneo/neo (neo/neo) mice were transplanted into lethally irradiated Dido+/+ mice. A total of 4 of 9 WT 
cell recipients and 3 of 9 Didoneo/neo cell recipients died shortly after transplant. Bone marrow, spleen, and blood from surviving mice were analyzed 5 weeks 
(B1, D1, D2, E1, E2, F1, and F2 mice) or 10 weeks (A1, A2, C1, and C2 mice) after transplant. ND, not determined. A–HSee Table 1 legend. Red and blue 
values, which indicate lesions in each mouse, denote severity and mildness of symptoms, respectively.
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genetic  alterations  is  currently 
under study.
Since many patients diagnosed 
with  myeloid  neoplasms  show 
reduced  hDido2  and  hDido3  but 
normal hDido1 levels, we propose 




esis,  we  are  currently  targeting 
exons shared by murine Dido2 and 
Dido3.  In contrast, many human 
and  murine  cell  lines  of  other 
























hDido expression abnomalities in myeloid neoplasms
	 Patients	showing	the	indicated	hDido	expression	abnormalities	(n°)	
Patient	group	 Reduced	hDido1	 Normal	hDido1	 Total	patients	with	
	 Reduced	hDido2	 Reduced	hDido2	 hDido	expression	
	 Reduced	hDido3	 Reduced	hDido3	 abnormalities	(%)
MDS/MPDs 3 of 6 3 of 6 100
MDSs 1 of 11 6 of 11 64
CMPDs 3 of 11 4 of 11 64
AML 0 of 9 3 of 9 33
CLL 0 of 13 0 of 13 0
Control BM 0 of 8 0 of 8 0
hDido1, hDido2, and hDido3 expression levels were analyzed by real-time quantitative PCR and Northern blot in bone 
marrow samples from healthy donors (control BM, n = 8) and patients diagnosed with MDS/MPD (n = 6), MDS (n = 11), 
CMPDs (n = 11), AML (n = 9), and CLL (n = 13). The number of patients showing either reduced hDido1, hDido2, and 
hDido3 expression or reduced hDido2 and hDido3 but relatively normal hDido1 expression levels is shown. The total 
percentage of patients tested who showed some type of hDido expression abnormality is indicated in the right column. 
n°, number of patients.
Figure 7
Severe reduction in hDido expression in bone marrow from MDS/MPD, MDS, and CMPD patients. (A) 
Relative hDido1, hDido2, and hDido3 expression levels were determined by real-time quantitative PCR. 
Ct increments relative to those of samples from a pool of healthy donors and actin (∆∆Ct) are shown for 
indicated patients. Note that a value of 3 in Ct increments indicates a 10-fold decrease in expression. (B) 
Northern blot analysis of hDido1, hDido2, and hDido3 expression in bone marrow samples of a healthy 
control donor (Ctl) and patients, indicated by numbers, diagnosed with various myeloid disorders. The 
blot was stained with methylene blue to control RNA loading. Positions of hDido transcripts and 28s 
and 18s RNA are indicated. Diagnosis of patients was as follows: chronic myelomonocytic leukemia 
(MDS/MPD), patients 15, 24, 25; refractory anemia (MDS), patients 2, 12, 17, 26, 30; polycythemia 
vera (CMPD), patients 7, 30; essential thrombocythemia (CMPD), patient 6; and refractory anemia with 
ringed sideroblasts (MDS), patient 23.
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Real-time quantitative PCR analysis. DNase  I-digested  total RNA was 












CCTCACCTCCACCCAGAAAG,  FAM-labeled  probe  CCGGCGCT-
TACCTGGT), and hDido3 (forward TTCCATCCAAACTCTTGCCCTTT, 
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